MPS1
Inhibitory Selectivity
MPS1 Products
| Catalog No. | Information | Product Use Citations | Product Validations |
|---|---|---|---|
| S2731 |
AZ 3146AZ3146 is a selective Mps1 inhibitor with IC50 of ~35 nM, contributes to recruitment of CENP-E (kinesin-related motor protein), less potent to FAK, JNK1, JNK2, and Kit. |
Dose response curves for the treatment of breast cancer cell lines in the absence or presence of escalating doses of the TTK inhibitor (TTKi) AZ3146. The survival of cells was measured using the CellTitre MTS/MTA assay carried out 6 days after treatment. Percentage survival (n ¼ 3 per dose) was calculated as the percentage of the signal from treated cells to that from control cells. |
|
| S8214 |
Empesertib (BAY1161909)Empesertib (BAY1161909, Mps1-IN-5), a derivative of triazolopyridine, is an orally bioavailable, selective inhibitor of the serine/threonine monopolar spindle 1 (Mps1) kinase with IC50 of <1 nM. Empesertib has potential antineoplastic activity. |
||
| S8911New |
BOS172722BOS172722 is a monopolar spindle 1 (MPS1) checkpoint inhibitor with IC50 of 11 nM, Ki of 0.11 nM. |
||
| S7488 |
MPI-0479605MPI-0479605 is an ATP competitive and selective inhibitor of mitotic kinase Mps1 with IC50 of 1.8 nM, >40-fold selectivity over other kinases. |
||
| S0426 |
Pim1/AKK1-IN-1Pim1/AKK1-IN-1 (LKB1/AAK1 dual inhibitor, MDK-2275) is a potent multi-kinase inhibitor with Kd of 35 nM, 53 nM, 75 nM and 380 nM for Pim1, AKK1, MST2 and LKB1, respectively. Pim1/AKK1-IN-1 also inhibits MPSK1 and TNIK. |
||
| S6768 |
CC-671CC-671 is a selectively dual inhibitor of TTK (human protein kinase monopolar spindle 1 [hMps1]) and CDC like kinase 2 (CLK2) with IC50s of 5 nM and 3 nM for TTK and CLK2, respectively. |
| Catalog No. | Information | Product Use Citations | Product Validations |
|---|---|---|---|
| S2731 |
AZ 3146AZ3146 is a selective Mps1 inhibitor with IC50 of ~35 nM, contributes to recruitment of CENP-E (kinesin-related motor protein), less potent to FAK, JNK1, JNK2, and Kit. |
Dose response curves for the treatment of breast cancer cell lines in the absence or presence of escalating doses of the TTK inhibitor (TTKi) AZ3146. The survival of cells was measured using the CellTitre MTS/MTA assay carried out 6 days after treatment. Percentage survival (n ¼ 3 per dose) was calculated as the percentage of the signal from treated cells to that from control cells. |
|
| S8214 |
Empesertib (BAY1161909)Empesertib (BAY1161909, Mps1-IN-5), a derivative of triazolopyridine, is an orally bioavailable, selective inhibitor of the serine/threonine monopolar spindle 1 (Mps1) kinase with IC50 of <1 nM. Empesertib has potential antineoplastic activity. |
||
| S8911New |
BOS172722BOS172722 is a monopolar spindle 1 (MPS1) checkpoint inhibitor with IC50 of 11 nM, Ki of 0.11 nM. |
||
| S7488 |
MPI-0479605MPI-0479605 is an ATP competitive and selective inhibitor of mitotic kinase Mps1 with IC50 of 1.8 nM, >40-fold selectivity over other kinases. |
||
| S0426 |
Pim1/AKK1-IN-1Pim1/AKK1-IN-1 (LKB1/AAK1 dual inhibitor, MDK-2275) is a potent multi-kinase inhibitor with Kd of 35 nM, 53 nM, 75 nM and 380 nM for Pim1, AKK1, MST2 and LKB1, respectively. Pim1/AKK1-IN-1 also inhibits MPSK1 and TNIK. |
||
| S6768 |
CC-671CC-671 is a selectively dual inhibitor of TTK (human protein kinase monopolar spindle 1 [hMps1]) and CDC like kinase 2 (CLK2) with IC50s of 5 nM and 3 nM for TTK and CLK2, respectively. |
